For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service at certain sites in the UK for patients who meet the eligibility criteria.
Here you can find out more about BRCA testing, what the AstraZeneca
Importance of BRCA testing women with ovarian cancer
BRCA testing can help define treatment for women with ovarian cancer, as well as identify
Identifying BRCA gene mutations can have huge implications both for the patient and for society:
- It can provide prognostic information – women with BRCAm have longer
treatment freeintervals and respond differently to platinum-based chemotherapy1
- It can open up treatment options – which can offer the chance of a longer period of
progression freesurvival for patients with relapsed disease. One example of such a treatment is Lynparza (olaparib) capsules*1,2
- It can also allow for predictive genetic testing and advice about screening and risk reductive surgery to be given to
at riskfamily members if the mutation is found to be germline – to minimise their chance of developing breast and/or ovarian cancer3
*Lynparza capsules are indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.2
For more information on Lynparza capsules, visit the Lynparza page here.